GlaxoSmithKline (GSK) has joined with University of North Carolina at Chapel Hill to pursue HIV cure strategies, The New York Times reports. The HIV Cure center will be established at the university and partner with a venture called Qura Therapeutics, jointly owned by GSK and UNC Chapel Hill. Qura will handle intellectual property, commercialization, manufacturing and governance of the center’s pursuits.